Other RCC Studies
2018 - VEGFi Tivozanib is effective, has high rate of complications. (1)
2018 - Combination avelumab (MAB for PD-L1) plus axitinib (VEGFi) in treatment-naive patients with advanced RCC has manageable safety profile and encouraging initial anticancer results. (2)
2018 - Combination avelumab (MAB for PD-L1) plus axitinib (VEGFi) in treatment-naive patients with advanced RCC has manageable safety profile and encouraging initial anticancer results. (2)
- Molina, Ana M., et al. "Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study." European Journal of Cancer 94 (2018): 87-94.
- Choueiri, Toni K., et al. "Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial." The Lancet Oncology (2018).